Literature DB >> 27877094

Raman Spectroscopy: A Sensitive and Specific Technique for Determining the Accuracy of Compounded Pharmaceutical Formulations.

Claudia Meek1, Jihye Hoe1, Jason Evans2, Rosanne Thurman2, Lisa Ashworth3, Richard Leff1.   

Abstract

OBJECTIVES: Raman spectroscopy is a widely used technology to identify chemical unknowns or confirm chemical identity. We have tested Raman spectrometry to identify compounded pharmaceutical formulations. In contrast to the commonly used application mentioned above, compounded pharmaceutical formulations contain a mixture of ingredients, and the Raman spectrometer is being used to correctly identify the composition of the complete pharmaceutical formulation, including the active pharmaceutical ingredient(s). The objective of this pilot study was to document the potential use of Raman spectroscopy as a tool to provide quality control to compounded pharmaceutical formulations.
METHODS: "Testing a test" study design was used to prospectively determine whether Raman spectroscopy could verify the accuracy of compounded pharmaceutical formulations. A total of 9 formulations that are commonly compounded at Cook Children's Health Center were selected for testing. Each of the 9 formulations and 2 blank controls were randomly tested for compounding accuracy in replicate. A total of 110 tests were conducted.
RESULTS: Raman spectroscopy was found to be a reliable test to determine the accuracy of compounded pharmaceutical formulations with a 100% positive predictive value.
CONCLUSIONS: Raman spectroscopy promises to be an excellent tool for compounding pharmacies to provide an objective measure of compounding accuracy to their unique, compounded pharmaceutical formulations.

Entities:  

Keywords:  Raman spectroscopy; pharmaceutical formulations; pharmacy compounding; quality control

Year:  2016        PMID: 27877094      PMCID: PMC5103648          DOI: 10.5863/1551-6776-21.5.413

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  12 in total

1.  Pediatric clonidine poisoning as a result of pharmacy compounding error.

Authors:  Jeffrey R Suchard; Kimberlie A Graeme
Journal:  Pediatr Emerg Care       Date:  2002-08       Impact factor: 1.454

2.  Investigation of product quality between extemporaneously compounded progesterone vaginal suppositories and an approved progesterone vaginal gel.

Authors:  Vorapann Mahaguna; J Mario McDermott; Feng Zhang; Felipe Ochoa
Journal:  Drug Dev Ind Pharm       Date:  2004       Impact factor: 3.225

Review 3.  Interventions of hospital pharmacists in improving drug therapy in children: a systematic literature review.

Authors:  Navneet Sanghera; Po-Yi Chan; Zahra F Khaki; Claire Planner; Kenneth K C Lee; Noël E Cranswick; Ian C K Wong
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

4.  Content variability of active drug substance in compounded oral 3,4-diaminopyridine products.

Authors:  D M Green; A C Jones; K R Brain
Journal:  J Clin Pharm Ther       Date:  2011-04-19       Impact factor: 2.512

5.  Quality of extemporaneously compounded nitroglycerin ointment.

Authors:  Daniel L Azarnoff; J C Lee; Charles Lee; John Chandler; David Karlin
Journal:  Dis Colon Rectum       Date:  2007-04       Impact factor: 4.585

6.  Severe accidental overdose of 4-aminopyridine due to a compounding pharmacy error.

Authors:  Eric Schwam
Journal:  J Emerg Med       Date:  2009-05-13       Impact factor: 1.484

Review 7.  Reducing medication errors and increasing patient safety: case studies in clinical pharmacology.

Authors:  David M Benjamin
Journal:  J Clin Pharmacol       Date:  2003-07       Impact factor: 3.126

Review 8.  Pharmacy compounding of high-risk level products and patient safety.

Authors:  Tamira Mullarkey
Journal:  Am J Health Syst Pharm       Date:  2009-09-01       Impact factor: 2.637

9.  Deaths from intravenous colchicine resulting from a compounding pharmacy error--Oregon and Washington, 2007.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2007-10-12       Impact factor: 17.586

10.  Quality investigation of hydroxyprogesterone caproate active pharmaceutical ingredient and injection.

Authors:  John L Chollet; Michael J Jozwiakowski
Journal:  Drug Dev Ind Pharm       Date:  2012-02-13       Impact factor: 3.225

View more
  1 in total

1.  Raman Mapping-Based Reverse Engineering Facilitates Development of Sustained-Release Nifedipine Tablet.

Authors:  Ningyun Sun; Liang Chang; Yi Lu; Wei Wu
Journal:  Pharmaceutics       Date:  2022-05-13       Impact factor: 6.525

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.